Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib Plus RICE for Patients With Relapsed/Refractory DLBCL Followed by Autologous Hematopoietic Cell Transplantation and Acalabrutinib Maintenance Therapy

NCT03736616 is registered in ClinicalTrials.gov with Swedish Medical Center as lead sponsor.

NCT NCT03736616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03736616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib Plus RICE for Patients With Relapsed/Refractory DLBCL Followed by Autologous Hematopoietic Cell Transplantation and Acalabrutinib Maintenance Therapy
Lead sponsor
Swedish Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
August 16, 2019
Completion date
September 30, 2023
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma